| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| Other Sizes |
| Targets |
Trielaidin does not have a defined primary pharmacological target. Its mechanism of action involves its incorporation into biological membranes, particularly affecting the plasmalogen content of heart mitochondria in rats. Researchers utilize this compound to explore the impact of trans fats on membrane fluidity, cellular metabolism, and lipid bilayer properties in model systems. Its biological activity is primarily studied in the context of lipid biochemistry and the effects of trans fatty acids on cellular structures.
|
|---|---|
| ln Vitro |
In vitro studies utilize Trielaidin to investigate the impact of trans fats on membrane fluidity and lipid bilayer properties in model systems. It is used as a substrate to determine the substrate specificity of extracellular lipases, such as those from *S. rimosus*. The compound has also been shown to have enzyme activities, including p-nitrophenyl phosphate esterase and caproic acid hydrolase.
|
| ln Vivo |
In vivo studies have shown that dietary administration of 1,2,3-trielaidoyl-rac-glycerol reduces serum cholesterol levels in rats compared to corn oil-fed control animals. This suggests that Trielaidin can have significant metabolic effects when consumed as part of the diet. Its impact on serum cholesterol makes it a subject of interest in nutritional and metabolic research.
|
| Enzyme Assay |
For non-cellular assays, Trielaidin is characterized by standard analytical techniques including HPLC, NMR, and mass spectrometry to confirm identity and purity. The compound can be evaluated as a substrate for lipase activity assays. Typical protocols involve incubating the compound with enzyme samples and measuring the release of fatty acids. Purity is typically ≥99%. Storage: Powder at -20°C for 3 years; in solvent at -80°C for 6 months or -20°C for 1 month.
|
| Cell Assay |
For in vitro cell-based studies, Trielaidin is used to explore the impact of trans fats on cellular metabolism and lipid bilayer properties. Cells are cultured under standard conditions and treated with the compound to assess effects on membrane fluidity and lipid composition. The compound is typically dissolved in appropriate organic solvents and diluted in cell culture medium. Appropriate controls should be included in the experimental design.
|
| Animal Protocol |
For in vivo animal studies, Trielaidin is typically administered via dietary supplementation to assess its effects on serum cholesterol levels and other metabolic parameters. Dosing solutions should be freshly prepared and administered according to specific protocols with appropriate control groups. Standard animal welfare guidelines should be followed for all in vivo studies.
|
| ADME/Pharmacokinetics |
Trielaidin has a molecular weight of 885.43 g/mol and molecular formula C₅₇H₁₀₄O₆. Storage: Powder at -20°C for up to 3 years; in solvent at -80°C for 6 months or -20°C for 1 month. Shipping: ambient temperature. The compound is a triglyceride that is insoluble in water but soluble in organic solvents.
|
| Toxicity/Toxicokinetics |
Trielaidin is for research use only and not for human therapeutic or diagnostic use. Standard laboratory safety practices should be followed when handling this chemical. Specific LD₅₀ values and detailed toxicological profiles have not been extensively reported for this compound. Appropriate personal protective equipment including gloves and safety glasses should be worn when handling the compound.
|
| Additional Infomation |
Trielaidin are triglycerides formed by the trans-esterification of the three hydroxyl groups of glycerol. Functionally, they are related to trans-oleic acid. It has been reported that fleshy Ganoderma lucidum contains Trielaidin, and relevant data are available. (Z)-9-octadecenoic acid 1,2,3-propanetriester.
Trielaidin (CAS 537-39-3) is also known as glyceryl trielaidate and 1,2,3-Trielaidoyl-rac-glycerol. It is a trans fat used as a biochemical tool to study the impact of trans fatty acids on membrane biology and lipid metabolism. It serves as a lubricant and surfactant in industrial settings. No clinical trials or regulatory approvals for human use exist, as the product is exclusively for research purposes. |
| Molecular Formula |
C57H104O6
|
|---|---|
| Molecular Weight |
885.43
|
| Exact Mass |
884.783
|
| CAS # |
537-39-3
|
| PubChem CID |
5364673
|
| Appearance |
White to off-white solid powder
|
| Density |
0.921g/cm3
|
| Boiling Point |
818.7ºC at 760mmHg
|
| Melting Point |
42ºC
|
| Flash Point |
302.6ºC
|
| Index of Refraction |
1.4381 (estimate)
|
| LogP |
18.097
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
53
|
| Heavy Atom Count |
63
|
| Complexity |
1010
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCC/C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC/C=C/CCCCCCCC)COC(=O)CCCCCCC/C=C/CCCCCCCC
|
| InChi Key |
PHYFQTYBJUILEZ-WUOFIQDXSA-N
|
| InChi Code |
InChI=1S/C57H104O6/c1-4-7-10-13-16-19-22-25-28-31-34-37-40-43-46-49-55(58)61-52-54(63-57(60)51-48-45-42-39-36-33-30-27-24-21-18-15-12-9-6-3)53-62-56(59)50-47-44-41-38-35-32-29-26-23-20-17-14-11-8-5-2/h25-30,54H,4-24,31-53H2,1-3H3/b28-25+,29-26+,30-27+
|
| Chemical Name |
2,3-bis[[(E)-octadec-9-enoyl]oxy]propyl (E)-octadec-9-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Ethanol: 10 mg/mL (11.29 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1 mg/mL (1.13 mM) (saturation unknown) in 10% EtOH + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear EtOH stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 1 mg/mL (1.13 mM) in 10% EtOH + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear EtOH stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1 mg/mL (1.13 mM) (saturation unknown) in 10% EtOH + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1294 mL | 5.6470 mL | 11.2939 mL | |
| 5 mM | 0.2259 mL | 1.1294 mL | 2.2588 mL | |
| 10 mM | 0.1129 mL | 0.5647 mL | 1.1294 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
